
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics is poised for significant growth as their product, the iLet Bionic Pancreas, has been well received in the market and their innovative solutions have the potential to greatly improve the lives of insulin-requiring people with diabetes. With a strong focus on expanding their product offerings and a solid financial outlook, the company is set to continue its trend of beating expectations and raising guidance. Despite some recent challenges, Beta Bionics is well positioned for success and is a top pick in the rapidly growing MedTech industry.
Bears say
Beta Bionics is a small cap med tech company that has faced significant pressure in its stock performance due to a softer SMID med tech environment. While the business is developing ahead of schedule and receiving positive attention on things like increased pharmacy new starts, a recent WL adds an element of uncertainty and distraction. With a current 2.9x forward EV/Sales multiple, we believe a discount is warranted given the company's faster revenue growth prospects, but expect the multiple to potentially re-expand to at least 4.5x, resulting in our $25 PT based on our '27E EV/Sales forecast.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares